{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T10:08:43Z","timestamp":1778926123597,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.tranon.2026.102743","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:47:10Z","timestamp":1776415630000},"page":"102743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression"],"prefix":"10.1016","volume":"68","author":[{"given":"Farrukh","family":"Afaq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya S.","family":"Pathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balabhadrapatruni V.S.K.","family":"Chakravarthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4295-9127","authenticated-orcid":false,"given":"Darshan Shimoga","family":"Chandrashekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Carskadon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer Al","family":"Diffalha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakshmi P.","family":"Kunju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nallasivam","family":"Palanisamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upender","family":"Manne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooryanarayana","family":"Varambally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102743_bib0001","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eururo.2016.07.008","article-title":"Intratumoral and intertumoral genomic heterogeneity of multifocal localized prostate cancer impacts molecular classifications and genomic prognosticators","volume":"71","author":"Wei","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.tranon.2026.102743_bib0002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/1078-0432.CCR-12-2910","article-title":"Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer","volume":"19","author":"Hoffman-Censits","year":"2013","journal-title":"Clin. cancer res.: off. j. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102743_bib0003","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","article-title":"Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer","volume":"27","author":"Attard","year":"2009","journal-title":"J. clin. oncol.: off. j. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102743_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000702","article-title":"Mouse HORMAD1 and HORMAD2, two conserved meiotic chromosomal proteins, are depleted from synapsed chromosome axes with the help of TRIP13 AAA-ATPase","volume":"5","author":"Wojtasz","year":"2009","journal-title":"PLoS. Genet."},{"key":"10.1016\/j.tranon.2026.102743_bib0005","doi-asserted-by":"crossref","first-page":"e2994","DOI":"10.1371\/journal.pone.0002994","article-title":"Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets","volume":"3","author":"Martin","year":"2008","journal-title":"PLoS. One"},{"key":"10.1016\/j.tranon.2026.102743_bib0006","first-page":"12","article-title":"TRIP13 localizes to synapsed chromosomes and functions as a dosage-sensitive regulator of meiosis","author":"Chotiner","year":"2024","journal-title":"Elife"},{"key":"10.1016\/j.tranon.2026.102743_bib0007","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.7150\/jca.66020","article-title":"Inducing Synergistic DNA Damage by TRIP13 and PARP1 inhibitors provides a potential treatment for hepatocellular carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.tranon.2026.102743_bib0008","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41598-024-84592-w","article-title":"Repeated ionizing radiation exposure induces TRIP13 expression, conferring radioresistance in lung cancer cells","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2026.102743_bib0009","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1093\/emboj\/cdf659","article-title":"Identification of a MAD2-binding protein, CMT2, and its role in mitosis","volume":"21","author":"Habu","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.tranon.2026.102743_bib0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nature04209","article-title":"Towards a proteome-scale map of the human protein-protein interaction network","volume":"437","author":"Rual","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102743_bib0011","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.cell.2005.08.029","article-title":"A human protein-protein interaction network: a resource for annotating the proteome","volume":"122","author":"Stelzl","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102743_bib0012","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1534\/genetics.111.129031","article-title":"Pch2 modulates chromatid partner choice during meiotic double-strand break repair in Saccharomyces cerevisiae","volume":"188","author":"Zanders","year":"2011","journal-title":"Genetics"},{"key":"10.1016\/j.tranon.2026.102743_bib0013","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/sj.onc.1207374","article-title":"The spindle checkpoint, aneuploidy, and cancer","volume":"23","author":"Bharadwaj","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102743_bib0014","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1038\/ncomms5527","article-title":"TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer","volume":"5","author":"Banerjee","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102743_bib0015","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1002\/1878-0261.12821","article-title":"TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status","volume":"14","author":"Agarwal","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2026.102743_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100951","article-title":"Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma","volume":"47","author":"Afaq","year":"2024","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2026.102743_bib0017","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/1878-0261.13201","article-title":"DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4\/STAT3 axis and the Wnt\/\u03b2-catenin pathway in colorectal cancer","volume":"16","author":"Agarwal","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2026.102743_bib0018","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nature06024","article-title":"Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer","volume":"448","author":"Tomlins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102743_bib0019","first-page":"644","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science (1979)"},{"key":"10.1016\/j.tranon.2026.102743_bib0020","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.tranon.2026.102743_bib0021","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1158\/0008-5472.CAN-08-2014","article-title":"A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer","volume":"68","author":"Han","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102743_bib0022","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/0008-5472.CAN-18-3987","article-title":"A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102743_bib0023","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s13046-024-03106-8","article-title":"Combination of dual JAK\/HDAC inhibitor with regorafenib synergistically reduces tumor growth, metastasis, and regorafenib-induced toxicity in colorectal cancer","volume":"43","author":"Bajpai","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102743_bib0025","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.3892\/ol.2016.5332","article-title":"TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion","volume":"12","author":"Kurita","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2026.102743_bib0026","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.7150\/ijbs.32718","article-title":"Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway","volume":"15","author":"Gao","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.tranon.2026.102743_bib0027","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ijbiomac.2018.09.168","article-title":"TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer","volume":"121","author":"Dong","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.tranon.2026.102743_bib0028","article-title":"Clinical significance and systematic expression analysis of the thyroid receptor interacting protein 13 (TRIP13) as human gliomas biomarker","volume":"13","author":"Chen","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.tranon.2026.102743_bib0029","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/jcmm.17278","article-title":"Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways","volume":"26","author":"Lan","year":"2022","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.tranon.2026.102743_bib0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/bjc.2011.490","article-title":"Identification of markers of prostate cancer progression using candidate gene expression","volume":"106","author":"Larkin","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102743_bib0031","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2012.117","article-title":"A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides","volume":"132","author":"van Kester","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.tranon.2026.102743_bib0032","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2020.08.023","article-title":"Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth","volume":"493","author":"Hu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2026.102743_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100773","article-title":"Epithelial-mesenchymal transition in cancer: a historical overview","volume":"13","author":"Ribatti","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.tranon.2026.102743_bib0034","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41580-024-00733-z","article-title":"Epithelial-mesenchymal transition in tissue repair and degeneration","volume":"25","author":"Youssef","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tranon.2026.102743_bib0035","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41419-018-0434-z","article-title":"TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer","volume":"9","author":"Sheng","year":"2018","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2026.102743_bib0036","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13046-021-01890-1","article-title":"HMGA1-TRIP13 axis promotes stemness and epithelial mesenchymal transition of perihilar cholangiocarcinoma in a positive feedback loop dependent on c-Myc","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102743_bib0037","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.2174\/0109298673255498231117100421","article-title":"TRIP13 activates glycolysis to promote cell stemness and strengthen doxorubicin resistance of colorectal cancer cells","volume":"31","author":"Liu","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tranon.2026.102743_bib0038","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41420-023-01632-6","article-title":"Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells","volume":"9","author":"Hu","year":"2023","journal-title":"Cell Death. Discov."},{"key":"10.1016\/j.tranon.2026.102743_bib0039","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaf035","article-title":"Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair","volume":"7","author":"Illuzzi","year":"2025","journal-title":"NAR. Cancer"},{"key":"10.1016\/j.tranon.2026.102743_bib0040","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death. Dis."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600080X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193652332600080X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:20:28Z","timestamp":1778923228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193652332600080X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S193652332600080X"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102743","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAA ATPase TRIP13 is overexpressed in prostate cancer and promotes tumor progression","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102743"}}